Regulatory FDA approves AstraZeneca’s Saphnelo for SLE Pharmaceutical TechnologyAstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE.Immunology & InflammationRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology AstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE. Immunology & Inflammation Read full story Post navigation Previous: Oruka surges as long-acting psoriasis drug shows early promiseNext: BioMarin acquires Amicus Therapeutics for $4.8bn Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
